Literature DB >> 29623600

Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients.

Ahmed M Tahon1, Magdy Z El-Ghanam2, Samy Zaky3, Tarek Mostafa Emran2, Ali M Bersy2, Fathiya El-Raey3, Elsayed A Z4,5, Amr M El Kharsawy2, Dina Johar6,7.   

Abstract

BACKGROUND: Egypt has high incidence of hepatocellular carcinoma (HCC). This is due to wide spread of hepatitis C virus (HCV) infection which is responsible for most of the cases of liver cirrhosis. The major diagnostic techniques for HCC include serum markers and various imaging modalities. Glypican 3 (GPC3) protein is highly expressed in HCC, but not in normal liver tissue. The significance of GPC3 as a predictor or diagnostic tool for human tumors other than HCC is unclear. AIM: To quantitatively assess the role of GPC3 in diagnosis of HCC in comparison to α-fetoprotein (AFP), ultrasonography (US), and computerized tomography (CT). PATIENTS AND METHODS: This cross-sectional study enrolled 85 subjects: 40 cirrhotic patients with primary HCC, 30 cirrhotic patients without HCC, and 15 healthy individuals. All patients were recruited from the Gastroenterology and Tropical Departments and outpatient clinics of New Damietta Hospital during the period from November 2010 to August 2012.
RESULTS: GPC3 is positive in some HCC patients with normal levels of AFP. AFP has lower sensitivity (67.5%) compared to higher sensitivity of GPC3 (82.5%), and near specificity (61.2%) to GPC3 (57.8%). CONCLUSION AND SIGNIFICANCE: The combined serum AFP and GPC3 significantly increased the sensitivity of HCC diagnosis. Although GPC3 is better than AFP in diagnosis of HCC, it still lacks the 100% sensitivity and specificity because some patients have negative or normal level of GPC3 (below the cutoff point 1.5 ng/ml) despite being diagnosed by triphasic CT.

Entities:  

Keywords:  Cirrhosis; Glypican-3; Hepatocellular carcinoma; Triphasic CT; Ultrasonography; Viral hepatitis; α-Fetoprotein

Mesh:

Substances:

Year:  2019        PMID: 29623600     DOI: 10.1007/s12029-018-0095-2

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  36 in total

Review 1.  Imaging features of hepatocellular carcinoma.

Authors:  S C H Yu; D T K Yeung; N M C So
Journal:  Clin Radiol       Date:  2004-02       Impact factor: 2.350

2.  The cyanmethemoglobin method for hemoglobin determination.

Authors:  D S AMATUZIO; F GRANDE; S WADA
Journal:  Minn Med       Date:  1962-04

3.  Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma.

Authors:  Mayumi Suzuki; Hidenori Shiraha; Tatsuya Fujikawa; Nobuyuki Takaoka; Naoki Ueda; Yutaka Nakanishi; Kazuko Koike; Akinobu Takaki; Yasushi Shiratori
Journal:  J Biol Chem       Date:  2004-12-06       Impact factor: 5.157

4.  Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.

Authors:  Mariana Capurro; Ian R Wanless; Morris Sherman; Gerrit Deboer; Wen Shi; Eiji Miyoshi; Jorge Filmus
Journal:  Gastroenterology       Date:  2003-07       Impact factor: 22.682

5.  Prevalence and epidemiological features of hepatocellular carcinoma in Egypt-a single center experience.

Authors:  A Rahman El-Zayadi; H Abaza; S Shawky; M K. Mohamed; O E. Selim; H M. Badran
Journal:  Hepatol Res       Date:  2001-02       Impact factor: 4.288

Review 6.  Review article: liver transplantation for HCC. Treatment options on the waiting list.

Authors:  L Bolondi; F Piscaglia; V Camaggi; G L Grazi; A Cavallari
Journal:  Aliment Pharmacol Ther       Date:  2003-06       Impact factor: 8.171

7.  Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.

Authors:  Tetsuya Nakatsura; Yoshihiro Yoshitake; Satoru Senju; Mikio Monji; Hiroyuki Komori; Yutaka Motomura; Seiji Hosaka; Toru Beppu; Takatoshi Ishiko; Hidenobu Kamohara; Hiroshi Ashihara; Toyomasa Katagiri; Yoichi Furukawa; Shigetoshi Fujiyama; Michio Ogawa; Yusuke Nakamura; Yasuharu Nishimura
Journal:  Biochem Biophys Res Commun       Date:  2003-06-20       Impact factor: 3.575

8.  Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma.

Authors:  Yoshitaka Hippo; Kiyotaka Watanabe; Akira Watanabe; Yutaka Midorikawa; Shogo Yamamoto; Sigeo Ihara; Susumu Tokita; Hiroko Iwanari; Yukio Ito; Kiyotaka Nakano; Jun-ichi Nezu; Hiroyuki Tsunoda; Takeshi Yoshino; Iwao Ohizumi; Masayuki Tsuchiya; Shin Ohnishi; Masatoshi Makuuchi; Takao Hamakubo; Tatsuhiko Kodama; Hiroyuki Aburatani
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

9.  Glypican-3 is overexpressed in human hepatocellular carcinoma.

Authors:  Young Kwan Sung; Sun Young Hwang; Mi Kyung Park; Mohammad Farooq; In Sook Han; Han Ik Bae; Jung-Chul Kim; Moonkyu Kim
Journal:  Cancer Sci       Date:  2003-03       Impact factor: 6.716

Review 10.  Hepatocellular carcinoma: an epidemiologic view.

Authors:  Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2002 Nov-Dec       Impact factor: 3.062

View more
  7 in total

1.  Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression.

Authors:  Neven A Hagag; Yasser B M Ali; Ahmed A Elsharawy; Roba M Talaat
Journal:  J Gastrointest Cancer       Date:  2020-03

2.  A highly sensitive strategy for glypican-3 detection based on aptamer/gold carbon dots/magnetic graphene oxide nanosheets as fluorescent biosensor.

Authors:  Guiyin Li; Wei Chen; Danhong Mi; Bo Wang; HaiMei Li; Guangxiong Wu; Ping Ding; Jintao Liang; Zhide Zhou
Journal:  Anal Bioanal Chem       Date:  2022-07-05       Impact factor: 4.478

3.  Plasma and Joint Fluid Glypican-3 Are Inversely Correlated with the Severity of Knee Osteoarthritis.

Authors:  Wanvisa Udomsinprasert; Ellie McConachie; Srihatach Ngarmukos; Nipaporn Theerawattanapong; Aree Tanavalee; Sittisak Honsawek
Journal:  Cartilage       Date:  2019-04-04       Impact factor: 4.634

4.  Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Agostino Colli; Tin Nadarevic; Damir Miletic; Vanja Giljaca; Mirella Fraquelli; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

5.  Diagnostic accuracy and prognostic significance of Glypican-3 in hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Donglei Jiang; Yingshi Zhang; Yinuo Wang; Fu Xu; Jun Liang; Weining Wang
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

6.  GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.

Authors:  Jing Ning; Shenyi Jiang; Xiaoxi Li; Yang Wang; Xuhong Deng; Zhiqiang Zhang; Lijie He; Daqing Wang; Youhong Jiang
Journal:  BMC Pulm Med       Date:  2021-06-10       Impact factor: 3.317

7.  Cobalt Chloride Induced Apoptosis by Inhibiting GPC3 Expression via the HIF-1α/c-Myc Axis in HepG2 Cells.

Authors:  Yaoyao Tong; Kun Tong; Qinghong Zhu; Yuqin Wu; Yi Yang; Jicai Zhang; Pei Hu; Shirong Yan
Journal:  Onco Targets Ther       Date:  2019-12-05       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.